drugset / Trial / NCT00528827

A Randomized, Double-blinded, Placebo-controlled, Dose-ranging Study of Cardene® I.V. in Pediatric Subjects With Hypertension

NCT00528827

Phase 2 Withdrawn Facet Biotech
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To define the relationship between Cardene I.V. dose, serum concentrations, and blood pressure reduction in pediatric subjects with hypertension.

Timeline

Start
2007-09
Primary completion
2008-12
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nicardipine Small molecule 0.5 ug/kg Intravenous
Subject Nicardipine Small molecule 2.5 ug/kg Intravenous
Subject Nicardipine Small molecule 5 ug/kg Intravenous

Indications